Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 7
1979 31
1980 37
1981 65
1982 64
1983 74
1984 71
1985 104
1986 91
1987 80
1988 78
1989 86
1990 106
1991 100
1992 113
1993 104
1994 105
1995 92
1996 107
1997 106
1998 108
1999 124
2000 123
2001 112
2002 110
2003 109
2004 104
2005 109
2006 130
2007 114
2008 131
2009 134
2010 140
2011 141
2012 137
2013 153
2014 160
2015 174
2016 166
2017 173
2018 173
2019 179
2020 163
2021 183
2022 161
2023 161
2024 171
2025 199
2026 144

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,399 results

Results by year

Filters applied: . Clear all
Page 1
Approach to the Patient With Prolactinoma.
Auriemma RS, Pirchio R, Pivonello C, Garifalos F, Colao A, Pivonello R. Auriemma RS, et al. J Clin Endocrinol Metab. 2023 Aug 18;108(9):2400-2423. doi: 10.1210/clinem/dgad174. J Clin Endocrinol Metab. 2023. PMID: 36974474 Free PMC article. Review.
Prolactinomas are the most common pituitary tumor histotype, with microprolactinomas being prevalent in women and macroprolactinomas in men. ...This article reviews different facets of prolactinomas and discusses approaches to the condition in more common clinical s …
Prolactinomas are the most common pituitary tumor histotype, with microprolactinomas being prevalent in women and macroprolactinomas …
Treatment of Prolactinoma.
Inder WJ, Jang C. Inder WJ, et al. Medicina (Kaunas). 2022 Aug 13;58(8):1095. doi: 10.3390/medicina58081095. Medicina (Kaunas). 2022. PMID: 36013562 Free PMC article. Review.
Prolactinomas are the commonest form of pituitary neuroendocrine tumor (PitNET), representing approximately half of such tumors. ...DAs have been the mainstay of prolactinoma management since the 1970s, initially with bromocriptine and more recently with cabergoline …
Prolactinomas are the commonest form of pituitary neuroendocrine tumor (PitNET), representing approximately half of such tumors. ...D …
[Prolactinoma].
Krysiak R, Okopień B, Marek B, Szkróbka W. Krysiak R, et al. Przegl Lek. 2009;66(4):198-205. Przegl Lek. 2009. PMID: 19708510 Review. Polish.
Prolactin-secreting tumours (prolactinomas) are benign neoplasms constituting about 40 percent of all pituitary tumours. ...The authors review the diagnosis and management of prolactinomas, including progress made in recent years....
Prolactin-secreting tumours (prolactinomas) are benign neoplasms constituting about 40 percent of all pituitary tumours. ...The autho …
Prolactinoma in postmenopausal women: a systematic review.
Carneiro MS, de Mira TAA, Yela DA, Benetti-Pinto CL. Carneiro MS, et al. Menopause. 2024 Feb 1;31(2):160-167. doi: 10.1097/GME.0000000000002303. Epub 2024 Jan 9. Menopause. 2024. PMID: 38194617
IMPORTANCE: Prolactinomas occurring during the reproductive period exhibit a characteristic behavior. ...OBJECTIVE: This study aimed to review and characterize the influence of menopause on prolactinoma behavior. EVIDENCE REVIEW: A systematic review of observational …
IMPORTANCE: Prolactinomas occurring during the reproductive period exhibit a characteristic behavior. ...OBJECTIVE: This study aimed …
MicroRNAs in Dopamine Agonist-Resistant Prolactinoma.
Wan X, Yan Z, Tan Z, Cai Z, Qi Y, Lu L, Xu Y, Chen J, Lei T. Wan X, et al. Neuroendocrinology. 2022;112(5):417-426. doi: 10.1159/000517356. Epub 2021 May 25. Neuroendocrinology. 2022. PMID: 34034260 Free article. Review.
Dopamine agonists (DAs) are preferred for the treatment of prolactinomas and are usually very effective. Nonetheless, 20-30% of bromocriptine- and approximately 10% of cabergoline-treated individuals exhibit resistance to DAs. ...Unfortunately, recent studies tended to foc …
Dopamine agonists (DAs) are preferred for the treatment of prolactinomas and are usually very effective. Nonetheless, 20-30% of bromo …
Prolactinoma through the female life cycle.
Cocks Eschler D, Javanmard P, Cox K, Geer EB. Cocks Eschler D, et al. Endocrine. 2018 Jan;59(1):16-29. doi: 10.1007/s12020-017-1438-7. Epub 2017 Nov 24. Endocrine. 2018. PMID: 29177641 Review.
Prolactinomas are the most common secretory pituitary adenoma. They typically occur in women in the 3rd-6th decade of life and rarely in the pediatric population or after menopause. ...This review discusses the current literature and clinical understanding of prolactino …
Prolactinomas are the most common secretory pituitary adenoma. They typically occur in women in the 3rd-6th decade of life and rarely …
Diagnosis and Management of Pituitary Adenomas: A Review.
Tritos NA, Miller KK. Tritos NA, et al. JAMA. 2023 Apr 25;329(16):1386-1398. doi: 10.1001/jama.2023.5444. JAMA. 2023. PMID: 37097352 Review.
Functioning tumors are those that produce an excess of normally produced hormones and include prolactinomas, somatotropinomas, corticotropinomas, and thyrotropinomas, which produce prolactin, growth hormone, corticotropin, and thyrotropin, respectively. ...For those requir …
Functioning tumors are those that produce an excess of normally produced hormones and include prolactinomas, somatotropinomas, cortic …
Management of Dopamine Agonist-Resistant Prolactinoma.
Maiter D. Maiter D. Neuroendocrinology. 2019;109(1):42-50. doi: 10.1159/000495775. Epub 2019 Mar 18. Neuroendocrinology. 2019. PMID: 30481756 Review.
For patients who harbor aggressive prolactinomas, radiotherapy may be considered. However, normal prolactinemia will eventually occur in only one-third of patients after many years. Finally, temozolomide may be a therapeutic option in malignant/aggressive prolactinomas …
For patients who harbor aggressive prolactinomas, radiotherapy may be considered. However, normal prolactinemia will eventually occur …
Prolactin-secreting adenomas: pathogenesis, diagnosis, and management.
Fleseriu M, Varlamov EV, Akirov A, Langlois F, Petersenn S, Melmed S. Fleseriu M, et al. Lancet Diabetes Endocrinol. 2025 Oct;13(10):874-890. doi: 10.1016/S2213-8587(25)00227-X. Epub 2025 Aug 25. Lancet Diabetes Endocrinol. 2025. PMID: 40876473 Review.
Radiotherapy is reserved for treatment-refractory prolactinomas. Multidisciplinary management and an individualised approach are key to maximising therapeutic responsiveness and optimising outcomes. In this Review, we assess evidence relating to pathogenesis, diagnosis, an …
Radiotherapy is reserved for treatment-refractory prolactinomas. Multidisciplinary management and an individualised approach are key …
Hyperprolactinemia and prolactinoma.
Romijn JA. Romijn JA. Handb Clin Neurol. 2014;124:185-95. doi: 10.1016/B978-0-444-59602-4.00013-7. Handb Clin Neurol. 2014. PMID: 25248588 Review.
Prolactinomas are the most frequent pituitary adenomas. In patients with prolactinomas the primary cause of hyperprolactinemia is excessive and autonomic production of prolactin by lactotroph cells. ...In general, cabergoline is the preferred treatment for micro- an …
Prolactinomas are the most frequent pituitary adenomas. In patients with prolactinomas the primary cause of hyperprolactinemia …
5,399 results